Jack Nathan Medical Corp.

Jack Nathan Medical Corp. (JNH.V), along with its affiliated entities, primarily delivers primary healthcare services under the Jack Nathan Health brand. These medical clinics are predominantly located within Walmart Supercentres. As of June 30, 2022, the company managed a substantial network of facilities: In Canada, 76 clinics were situated inside Walmart locations across various provinces, including British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, and Quebec. Additionally, the Canadian portfolio included 4 standalone clinics operating independently of Walmart, alongside 18 general medical clinics, 2 rehabilitation centers, and 5 MedSpa facilities. In Mexico, Jack Nathan Medical Corp. had a significant presence with 108 corporate-owned and operated clinics, all established within Walmart Supercentres. The company was founded in 2006 and has its corporate headquarters situated in Woodbridge, Canada.

Jack Nathan Medical Corp. trades as JNH.V on TSXV. The company is classified in Healthcare / Medical - Care Facilities and reports in CAD.

The current profile places the business in Medical - Care Facilities. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $8.71M of revenue and $7.46M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Jack Nathan Medical Corp. can be compared against peers such as Albert Labs International Corp., Aquarius Surgical Technologies Inc., Bioasis Technologies Inc., ChitogenX Inc., Biocure Technology Inc., Global Hemp Group Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $413,492, beta of -0.19, and return on equity of +563.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

JNH.V currently shows total debt of $243,313 and beta of -0.19. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.jacknathanhealth.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.